Glaucoma, patients with excessive wound healing after trabeculectomy. Eye Diseases Glaucoma
Conditions
Interventions
Topical ranibizumab eyedrops (2mg/ml) four times daily for 1 month or placebo (BSS 4x/d for 1 month
Sponsors
Horten Center, University of Zurich (Switzerland)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with primary open angle glaucoma (POAG), PEX and pigment dispersion Glaucoma 2. At least 18 years of age 3. No previous intraocular surgery undergoing trabeculectomy or phaco-trabeculectomy
Exclusion criteria
Exclusion criteria: 1. Patients with primary angle closure glaucoma (PACG) 2. Glaucoma due to other causes 3. Previous intra- and extraocular surgery 4. Any surgery during the last 3 months 5. Patients with uveitis or inflammatory ocular surface disease 6. Patients with single eyes 7. Patients presenting the first postoperative day with bleb leak, hypotony or situations that potentially need another surgery 8. Pregnant and breast feeding women 9. Women planning to get pregnant
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Differences in the intraocular eye pressure, measured at 4 weeks, 3 and 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Bleb appearance / vascularisation using a standardized photography and the Moorfields bleb grading system 2. Postoperative intraocular pressure 3. Conjunctival wound healing problems All outcomes will be measured at 4 weeks, 3 and 6 months. | — |
Countries
Switzerland
Outcome results
None listed